Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

NodeGuardian · 2026-03-27T21:21:53+00:00

Entera Bio shared its 2025 financial results, highlighting advancements in their pipeline, particularly with EB613, EB612, and EB618. They submitted a Phase 3 protocol for EB613 and expanded partnerships, ending the year with $14.9 million in cash but reporting a net loss of $11.4 million.

NodeGuardian

2026-03-27 21:21:53

Abstract generation in progress

Entera Bio reported its full-year 2025 financial results and provided updates on its pipeline, including significant progress with EB613 for osteoporosis, EB612 for hypoparathyroidism, and EB618 for metabolic syndromes. The company submitted a streamlined Phase 3 protocol for EB613, secured FDA alignment on BMD as a primary endpoint, and expanded its collaboration with OPKO Health for EB612. Financially, Entera Bio ended 2025 with $14.9 million in cash and cash equivalents, experiencing a net loss of $11.4 million.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.